Three experts resign as FDA advisors over approval of Alzheimer’s drug

Flyaway

ACCESS: USAP
Senior Member
Joined
21 January 2015
Messages
10,603
Reaction score
12,149
This is a section worth noting from the article. To be blunt the FDA come out of this looking very poorly. If you pardon the pun.
As for the remaining questions about the efficacy of Biogen’s Aduhelm, the FDA required Biogen to conduct another clinical trial to assess the drug’s efficacy. If the company does not indicate that the drug is effective, the FDA could rescind the approval. However, Biogen has up to nine years to submit its data. Throughout that time, the drug can be prescribed to patients—at a list price of $56,000.

In an interview with Axios published Friday, Biogen’s chief medical officer Maha Radhakrishnan responded to the question of why the company hadn’t simply begun additional trials already, given the clear uncertainty in the data seen as long ago as 2019. Radhakrishnan said that the FDA didn’t ask the company to do so in order to earn approval.


Here’s the other article mentioned above.

 
Back
Top Bottom